Investor Relations

Board of Directors & Scientific Board

Board of Directors & Scientific Board

Board of Directors

  • Robert Bitterman

    Robert Bitterman


    Mr. Bitterman currently serves as the President & CEO of Cutanea Life Sciences, Inc., a wholly owned subsidiary of Maruho Company, LTD., a specialty pharma development company focused on diseased and aging skin. Mr. Bitterman has over 18 years of executive leadership experience in the pharmaceutical and biologic life science industry. Prior to Cutanea, he served as President and CEO for Isolagen, Inc., an international, public, bioscience technology company where the primary proprietary platform used human fibroblasts for soft tissue enhancement. For 10 years, Mr. Bitterman served as the President and GM of Aventis’ Dermik Laboratories, a global, strategic business unit focused on therapeutic and aesthetic dermatology development and commercialization. Prior to assuming senior operational leadership positions, Mr. Bitterman held various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University.

    Chairman of the Board
  • Keith Brownlie

    Keith Brownlie


    Mr. Brownlie comes to Phio after a distinguished career with Ernst & Young that spanned 36 years. During his tenure, he rapidly became one of the leading accounting specialists for life sciences companies of the greater New York area. For the last 20 years at Ernst & Young, he has held the position of Metro New York Area Life Sciences Industry Leader. Mr. Brownlie has extensive experience with SEC registration statements, initial public offerings and recurrent reporting. In his accounting career he has been involved in over 100 public offerings. Until 2010, when he retired from Ernst & Young, he was a member of Ernst & Young’s National Life Sciences Committee, and he is a member of the American Institute of CPAs. Mr. Brownlie is currently a member of the Board of Directors of Epicept and Soligenix, where in both companies he also is chairman of the Audit Committee.

  • Geert Cauwenbergh, Dr. Med. Sc.

    Geert Cauwenbergh, Dr. Med. Sc.


    Dr. Cauwenbergh joined Phio Pharmaceuticals Corp. in April of 2012. Prior to joining Phio, Dr. Cauwenbergh served as Chairman and Chief Executive Officer of Barrier Therapeutics, Inc., a publicly-traded biopharmaceutical company he founded in 2001 that focused on dermatology drug development. Barrier was acquired by Stiefel Laboratories, Inc. in 2008. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years. As Vice President, Research and Development for Johnson & Johnson’s Skin Research Center, he was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies. He is a member of the board of directors of Cutanea Life Sciences and Moberg Pharmaceuticals. In 2005, Dr. Cauwenbergh was inducted into the New Jersey High-Tech Hall of Fame, and, from 2009 to 2010, he served as Chairman of the Board of Trustees of BioNJ. He has authored more than 100 publications and has been a guest editor for a number of books in mycology and infectious diseases. Dr. Cauwenbergh received his Doctorate in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine (Belgium), where he also completed his masters and undergraduate work.

    • H. Paul Dorman

      H. Paul Dorman


      Mr. Dorman brings nearly three decades of executive experience in the pharmaceutical industry with Johnson & Johnson and Baxter, in various leadership roles, to Phio. He currently serves as Chairman and CEO of DFB Pharmaceuticals, a Fort Worth, TX based holding company that, over the last 20 years, has successfully invested in and operated multiple pharmaceutical businesses. In that role, he acquired several companies, three of which were turned around to profitability, from Chapter 11 status at acquisition, and later sold to a large, multi-national, public corporation. He holds a Bachelor of Science degree in Mechanical Engineering from Tulane University and a Juris Doctor of Law from Loyola University.

    • Dr. Jonathan Freeman

      Dr. Jonathan Freeman


      Dr. Jonathan Freeman serves as the Chief Business Officer at Vedanta Biosciences, a privately-held company developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. Previously, Dr. Freeman was Senior Vice President, Head of Strategy Development and Portfolio Management at Merck KGaA.  During his tenure, Jonathan was responsible for the portfolio and strategic shift that repositioned Merck as a major player in the immuno-oncology space. Prior to that role, he was the Head of Global Business Development and Licensing at Merck executing more than 30 transactions and structured financings.  Prior to his roles at Merck, Jonathan served in senior positions at Baxter and Serono, in M&A and, Corporate and Business Development, respectively.  Jonathan holds a First Class Honours in Biochemistry and an MA from Cambridge University, UK, a PhD in cancer research from the Imperial Cancer Research Fund (now CRUK), and an MBA with a finance major from Webster University, St. Louis.  He held various post-doctoral positions in the Swiss Institute for Cancer Research (ISREC), and the Geneva Medical School (CMU).
    • Curtis Lockshin, Ph.D.

      Curtis Lockshin, Ph.D.


      Dr. Lockshin comes to Phio providing exceptional industry insight and functional, hands-on experience. He currently serves as the CEO of Guardum Pharmaceuticals, LLC in Lexington, MA, a wholly owned US subsidiary of OJSC Pharmsynthez which is headquartered in St. Petersburg, Russia. Prior to this role, Dr. Lockshin served as Vice President, Corporate R&D Initiatives for OPKO Health, Inc., with operational responsibilities inside several of OPKO’s R&D units. He currently serves as a Director of the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. He previously served as a Director of Sorrento Therapeutics and Winston Pharmaceuticals. He initially began his career as a scientist with Sepracor and eventually became the research director responsible for the strategy and operations of Sepracor’s new leads initiative. He is a Co-Inventor on several U.S. patents and applications, covering pharmaceuticals, biomaterials, and optics for remote biochemical sensing. Dr. Lockshin holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology.

    Scientific Advisory Board

    • James D. Griffin, M.D.

      James D. Griffin, M.D.

      James D. Griffin, MD is the Chairman, Department of Medical Oncology at the Dana-Farber Cancer Institute; Professor, Medicine at Harvard Medical School and Director, Medical Oncology at Brigham and Women's Hospital. Dr. Griffin received his medical degree from Harvard Medical School in 1974. After residency training in internal medicine at Johns Hopkins Hospital, he completed a hematology fellowship at Massachusetts General Hospital and a medical oncology fellowship at Dana-Farber. In 1981, he joined the staff of Dana-Farber, where he is chair of the Department of Medical Oncology. From 1993 to 1998, Dr. Griffin was editor-in-chief of Blood. He is a professor of Medicine at Harvard Medical School and currently sits on the scientific advisory boards of the Lombardi Cancer Center at Georgetown University and the Johns Hopkins Cancer Center and Case Western Cancer Center.

      • Rolf Kiessling, M.D.

        Rolf Kiessling, M.D.

        Rolf Kiessling is a Professor in Experimental Oncology at the Karolinska Institutet and Senior Chief Physician of Radiumhemmet at Karolinska Hospital. Dr. Kiessling has broad scientific expertise in the field of experimental and clinical immunology and accredited with the discovery for Natural Killer cells (NK cells) during the mid-70’s. He has published more than 250 publications in peer-reviewed journals. Professor Kiessling has served as a Member of the Research Council at the Swedish Cancer Society and the Swedish Association for Medical Research.

        • Pamela Pavco, Ph.D.

          Pamela Pavco, Ph.D.

          Dr. Pavco has over 20 years of research and development experience in oligonucleotides. Dr. Pavco served as Phio's Chief Development Officer until May 2017. Prior to that, she joined Galena Biopharma, Inc. in March of 2007 and served served as the Senior Vice President of Pharmaceutical Development until April 2012. Dr. Pavco was Senior Director, Research and Development Project Management at Sirna Therapeutics, Inc., from 2002 until 2006, when it was acquired by Merck & Co., Inc. for $1.1 billion. While at Sirna, she was responsible for the discovery research and development of Sirna-027, the first chemically modified siRNA to enter clinical trials. Dr. Pavco also managed Sirna’s alliance with Allergan, Inc. that was initiated to continue discovery research in the area of ophthalmology and take Sirna-027 forward into Phase 2 clinical studies. While at Sirna, Dr. Pavco served in various additional capacities, including Director of Biology Research and Director of Pharmacology and she also managed numerous corporate collaborations and internal programs focusing on the development of therapeutic oligonucleotides in the fields of oncology, anti- angiogenesis, hepatitis, respiratory disease and Huntington’s disease. Dr. Pavco has authored numerous scientific articles and contributed to approximately 58 patents and patent applications in the oligonucleotide therapeutics field. Dr. Pavco received a Ph.D. in Biochemistry from Virginia Commonwealth University in 1983 and did her post-doctoral work at Duke University. She is a member of the American Association of Cancer Research and the Association for Research and Vision in Ophthalmology.